Moderna Prices Upsized $2.6 Billion Zero-Coupon Convertible Note Offering

Moderna priced an upsized $2.6 billion offering of 0.00% convertible senior notes due 2032, increasing the size from the $2.0 billion it had initially proposed as the biotechnology company adds long-term financing flexibility while continuing to fund a broad development pipeline. The private placement is being sold to qualified institutional buyers under Rule 144A, and Moderna expects the sale to close on September 1, subject to customary conditions.

The notes will be senior unsecured obligations, will not pay regular interest and will not accrete in principal value. They mature on March 1, 2032 unless converted, redeemed or repurchased earlier. Moderna also gave the initial purchasers an option to buy up to another $400 million of notes during a 13-day period beginning when the notes are first issued, meaning the total principal amount could reach $3.0 billion if that option is exercised in full.

By choosing a zero-coupon convertible rather than conventional interest-bearing debt, Moderna can raise a large amount of capital without adding regular cash interest payments. The trade-off is a future principal obligation and the possibility of equity dilution if the share price rises enough to make conversion attractive. That balance is especially relevant as the company continues to absorb substantial research, development and operating costs after the decline in pandemic-era COVID vaccine revenue.

Upsizing lifts expected proceeds and sets a high conversion threshold

In the pricing announcement, Moderna estimated net proceeds of about $2.5629 billion after the initial purchasers’ discount and offering expenses. If the extra $400 million option is exercised in full, estimated net proceeds would rise to about $2.9573 billion. The company expects to use roughly $285 million of the proceeds to pay for capped-call arrangements, with the remainder available for general corporate purposes.

The initial conversion rate is 4.7487 shares of Moderna common stock for each $1,000 principal amount of notes. That is equivalent to an initial conversion price of about $210.58 per share, which Moderna said represents a 47.5% premium to the $142.77 last reported sale price of its shares on Nasdaq on August 27. Holders will be able to convert only under specified conditions before the final conversion period, and Moderna may settle conversions in cash, shares or a combination of the two.

The capped calls are designed to reduce potential dilution from conversions, or offset cash payments above principal that Moderna could owe when converted notes are settled, subject to an upper limit. The initial cap price is $392.6175 per share, or 175% above the August 27 reference price. That hedge provides more protection than the conversion premium alone, but it does not eliminate dilution or economic exposure if Moderna’s stock rises beyond the cap or if other terms of the notes come into play.

Before September 6, 2029, the notes generally cannot be redeemed by Moderna apart from a specified cleanup redemption. After that date, the company may redeem some or all of them if its share price meets the threshold set in the note terms, including a condition tied to the stock trading at least 130% of the then-current conversion price for the required number of days. The structure therefore provides a long period without scheduled cash interest, but the principal still must ultimately be repaid, converted or otherwise settled.

The financing arrives while Moderna is still using cash

As of June 30, Moderna still had a sizable liquidity base, but its latest financial statements also show the scale of its ongoing cash needs. The company’s quarterly report filed with the SEC showed $6.91 billion of cash, cash equivalents and investments, down from $8.14 billion at the end of 2025. Cash and cash equivalents alone were $1.72 billion, with the balance held mainly in current and non-current marketable securities.

During the first six months of the year, cash, cash equivalents and investments fell by about $1.2 billion, primarily because Moderna used roughly $1.2 billion of cash in operating activities and spent $99 million on property and equipment. The second quarter produced $145 million of total revenue and a GAAP net loss of $782 million. Those figures show a company with substantial financial resources but also a business that is still spending far more than its current quarterly revenue base as it develops and commercializes new products.

Long-term debt stood at $591 million on the June 30 balance sheet, representing a $600 million principal term loan net of issuance costs and discount. In its July financial update, Moderna projected year-end 2026 cash and investments of $4.7 billion to $5.2 billion, excluding any further drawdowns from the remaining $0.9 billion available under its credit facility. That forecast predates the new convertible financing, so it would be misleading simply to add the gross proceeds to the earlier year-end range. Capped-call costs, possible debt repayment, operating cash use and other capital needs will affect the eventual balance.

A zero-coupon convertible can reduce near-term cash interest expense compared with conventional debt, but it is not costless financing. Investors accept no regular coupon partly because the notes carry conversion value, and the company takes on a future repayment obligation together with potential dilution if its stock appreciates. The capped-call hedge is intended to soften that dilution over a defined price range rather than remove it entirely.

Oncology is a possible use of proceeds, not an earmark

The use-of-proceeds language is deliberately broad. After paying for the capped calls, Moderna said the remaining money will be used for general corporate purposes and may provide flexibility to invest in the growth of its oncology business and repay debt. It did not dedicate a fixed amount of the $2.6 billion offering to oncology or specify how much debt it intends to repay, so the financing should not be treated as a project-specific raise.

Oncology is nevertheless one of Moderna’s most capital-intensive strategic areas. Its June-quarter filing said the company and Merck are advancing intismeran autogene, also known as mRNA-4157, in nine Phase 2 and Phase 3 studies across melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma. A Phase 3 adjuvant melanoma study is fully enrolled, and Moderna has said data could become available in 2026. The company also has a wholly owned cancer-antigen therapy, mRNA-4359, in a Phase 1/2 study.

Research and development expense was $651 million in the second quarter, down from $700 million a year earlier, while first-half R&D expense totaled $1.30 billion. Moderna has been cutting costs and prioritizing its pipeline, but its regulatory filings still warn that late-stage development, oncology programs, manufacturing and commercial infrastructure will require significant future cash outlays. That makes the convertible offering relevant not just as a debt-market event, but as part of the company’s broader effort to preserve financial capacity while it waits for more products and late-stage programs to generate returns.

The first concrete milestone for the financing is the expected September 1 closing. After that, investors will be able to see whether the initial purchasers use the additional $400 million option and, in later filings, how Moderna allocates the new capital between operating needs, oncology investment, debt repayment and other corporate purposes.